We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+31.92%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$321M
AUM Growth
-$45.3M
Cap. Flow
-$88.3M
Cap. Flow %
-27.53%
Top 10 Hldgs %
87.56%
Holding
25
New
2
Increased
1
Reduced
1
Closed
3

Top Buys

Rank Stock Value
1
FOMX
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
+$7.15M
2
CLCD
CoLucid Pharmaceuticals, Inc.
CLCD
+$3.33M
3
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
+$3.19M

Top Sells

Rank Stock Value
1
SGNT
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
+$97.3M
2
NERV icon
Minerva Neurosciences
NERV
+$2.04M
3
LITS
Lite Strategy Inc
LITS
+$1.5M
4
CDXS icon
Codexis
CDXS
+$1.17M

Sector Composition

Rank Sector Weight
1 Healthcare 91.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACRS icon
1
Aclaris Therapeutics
ACRS
$739M
$107M 33.45%
4,191,397
– –
ASND icon
2
Ascendis Pharma A/S
ASND
$16.3B
$35.5M 11.07%
1,766,832
– –
EIGR
3
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$23.9M 7.46%
59,570
+6,250
+12% +$3.19M
CDXS icon
4
Codexis
CDXS
$136M
$23.5M 7.33%
5,294,825
-278,494
-5% -$1.17M
NBRV
5
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$22.2M 6.92%
12,607
– –
AAAP
6
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$17.4M 5.41%
455,798
– –
AGRX
7
DELISTED
Agile Therapeutics
AGRX
$14.1M 4.39%
1,010
– –
RGNX icon
8
Regenxbio
RGNX
$606M
$13.9M 4.32%
990,449
– –
TRVN
9
DELISTED
Trevena, Inc.
TRVN
$11.7M 3.63%
2,765
– –
AIMT
10
DELISTED
Aimmune Therapeutics
AIMT
$11.4M 3.57%
763,009
– –
CLCD
11
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
$8.58M 2.68%
+225,000
New +$3.33M
FOMX
12
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$7.92M 2.47%
+855,000
New +$7.15M
SLNO
13
DELISTED
Soleno Therapeutics
SLNO
$6.71M 2.09%
99,426
– –
AKTX
14
Akari Therapeutics
AKTX
$14.4M
$4.49M 1.4%
660
– –
SRRA
15
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$4.44M 1.38%
60,957
– –
DVAX
16
DELISTED
Dynavax Technologies
DVAX
$3.77M 1.18%
359,828
– –
KALV
17
DELISTED
KalVista Pharmaceuticals
KALV
$1.93M 0.6%
300,326
– –
RVNC
18
DELISTED
Revance Therapeutics, Inc.
RVNC
$1.25M 0.39%
77,373
– –
OCRX
19
DELISTED
Ocera Therapeutics, Inc.
OCRX
$405K 0.13%
153,331
– –
CAPNW
20
DELISTED
Capnia, Inc. Series A Warrant
CAPNW
$198K 0.06%
943,858
– –
PTN
21
Palatin Technologies
PTN
$13.4M
$148K 0.05%
188
– –
ZSAN
22
DELISTED
Zosano Pharma Corporation
ZSAN
$78K 0.02%
141
– –
LITS
23
Lite Strategy Inc
LITS
$33.4M
– –
-55,056
Closed -$1.5M
NERV icon
24
Minerva Neurosciences
NERV
$196M
– –
-25,000
Closed -$2.04M
SGNT
25
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
– –
-6,495,416
Closed -$97.3M

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
WC
Whitney & Co Rochester, New York $1.2B AUM 24.16% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
RCYC
Richard C. Young & Co Newport, Rhode Island $1.21B AUM 38.41% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

Vivo Capital's Q3 2016 Portfolio in Review

As of Q3 2016, Vivo Capital held 25 positions worth $321M, down 12% from $366M the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Vivo Capital withdrew a net $88.3M in Q3 2016, closing 3 positions and reducing 1 holding. Its most notable exit was SAGENT PHARMACEUTICALS INC COM STK (DE), an estimated $97.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 67% a quarter earlier.

Against the trend, Vivo Capital opened a new position in Foamix Pharmaceuticals Ltd. Ordinary Shares worth $7.92M.

  • Vivo Capital's largest Q3 2016 buy was Foamix Pharmaceuticals Ltd. Ordinary Shares: 855,000 shares worth $7.92M.
  • Vivo Capital added most to Eiger BioPharmaceuticals, Inc. in Q3 2016, an estimated $3.19M increase.
  • Vivo Capital's biggest Q3 2016 reduction was Codexis, cutting an estimated $1.17M.
  • Vivo Capital fully exited SAGENT PHARMACEUTICALS INC COM STK (DE) in Q3 2016, selling an estimated $97.3M.
  • Vivo Capital's ten largest holdings make up 88% of its $321M portfolio in Q3 2016.
  • Vivo Capital opened 2 new positions and closed 3 in Q3 2016.
  • Vivo Capital's portfolio value fell 12% quarter-over-quarter to $321M.

Based on Vivo Capital's 13F filing for Q3 2016, filed 14 Nov 2016.